Tag Archives: R&D

Let’s talk about #SciComm

Posted on by

Science communication is a young field with many voices and few guidelines. Let’s find a way to combine our voices in order to protect the integrity of research endeavors, says Judith Reichel.

There are plenty of reasons to become active in the field of science communication, and for many early career researchers (ECRs) still exploring research, it’s a great way to find their niche and voice their opinions.

Yet, like many of its participants, the field of science communication itself is fairly young, and is constantly evolving from its original aim — to translate scientific findings to the public, in order to raise awareness and funding for the grand scientific endeavor. When 3000 new academic papers are published every day, it‘s impossible for any single scientist to keep track of every development.

GettyImages-550382899-smaller

Science communication is practiced by a range of journalists, editors, freelance writers and free-time writers, yet the aim remains the same: to communicate important findings in quick soundbites that provide enough information for scientists but are still digestible to the general public. Continue reading →

#scidata16 keynote highlights: “Research data management for early career researchers”

Posted on by

Data management is a crucial component of scientific research and one that should be tackled by early career researchers before they become swamped with data, says Erica Brockmeier.

Network_Visualization

 

PhD students and early career researchers have a lot on their to-do lists, everything from writing papers and applying for grants to staying on top of the latest findings in their field. The third keynote of the #scidata16 conference highlighted yet another important facet of a research career: data management. Kevin Ashley, based at the University of Edinburgh, gave a thought-provoking presentation on this topic. As director of the Digital Curation Centre in Edinburgh, Scotland, Mr. Ashley and his team provide advice, guidance and training for researchers, alongside consultancy services on all aspects of data management and data reuse. Continue reading →

Thinking of a PhD? This is the Australian story

Posted on by

Advice for prospective PhD candidates focuses on career prospects in R&D, but more thought should be given to personal aspirations in life and work.

Research is fuelled by the energy of post-graduate students. PhD students contribute 57% of total university research output, according to a 2013 discussion paper from The Group of Eight Universities in Australia. In 2011 Nature published “The PhD factory,” which described the ongoing crisis caused by the oversupply of trained researchers and the inability of academia and industry to soak up the overflow.

CSIRO_ScienceImage_3881_Five_Antennas_at_Narrabri_-_restoration1

Five of the Australia Telescope Compact Array antennas at Narrabri, New South Wales

Fast forward to 2016, and the PhD factories are just as productive, if not even more so. In the 2011 article, Dr Anne Carpenter at Harvard/MIT’s Broad Institute fought the system by hiring permanent staff scientists instead of the usual mix of postdocs and graduate students. She struggled to justify her high staff cost to grant-review panels. Continue reading →

AstraZeneca to cut 2,200 R&D jobs

Posted on by
Reply

As part of a major restructuring programme, pharmaceutical company AstraZeneca announced yesterday it would be cutting 2,200 jobs from its research and development (R&D) workforce.

The bulk of job losses will affect employees in its neuroscience arm as the company looks to outsource more of its R&D via external collaborations. It will set up a ‘virtual’ neuroscience research unit comprising 40 to 50 AstraZeneca scientists working with partners in academia and industry, such as the Karolinska Institute in Sweden. The unit will be based in Boston, United States, and Cambridge, United Kingdom, while R&D activities will cease at two sites that are focused on neuroscience: Södertälje in Sweden and Montreal in Canada.

In a statement, AstraZeneca’s president of R&D, Martin Mackay, said: “We’ve made an active choice to stay in neuroscience though we will work very differently to share cost, risk and reward with partners in this especially challenging but important field of medical research.”